Literature DB >> 7082547

The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.

M J Vandenburg, P Wright, J Holmes, H J Rogers, R A Ahmad.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082547      PMCID: PMC1402085          DOI: 10.1111/j.1365-2125.1982.tb01452.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype.

Authors:  S N Hunyor
Journal:  Aust N Z J Med       Date:  1975-12

2.  Relation of hydralazine plasma concentration to dosage and hypotensive action.

Authors:  R Zacest; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

3.  The polymorphic acetylation of dapsone in man.

Authors:  R Gelber; J H Peters; G R Gordon; A J Glazko; L Levy
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

4.  Hydralazine slow-release: observations on serum profile and clinical efficacy in man.

Authors:  T Talseth; P Fauchald; J F Pape
Journal:  Curr Ther Res Clin Exp       Date:  1977-02

5.  Hydrallazine with beta-blocker and diuretic in the treatment of hypertension. A double-blind crossover study.

Authors:  S Kalowski; A S Hua; J A Whitworth; P Kincaid-Smith
Journal:  Med J Aust       Date:  1979-10-20       Impact factor: 7.738

6.  Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.

Authors:  R A Ahmad; H J Rogers
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

  6 in total
  2 in total

1.  Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?

Authors:  L E Ramsay; J H Silas; J D Ollerenshaw; G T Tucker; F C Phillips; S Freestone
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 2.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.